NASDAQ
UTMD
Last Price
US $72.1
KEY FIGURES
MKT CAP
$229.6M
EPS
TTM
$3.29
EPS Growth (1Y)
-12.12%
PEG
TTM
6.38x
P/E
TTM
21.89x
P/S
TTM
6.36x
YIELD
1.71%
GROWTH (5Y CAGR)
Profit margin
Current Ratio
Capital Returns
8.74%
Return on equity
ROIC: 6.83%
Valuation History
22.4X
Price to Earnings
EV/EBITDA: 15.7X
Cash flow
Profit margin
Revenue
-1.80%
EBITDA
-3.99%
Cash flow
-5.77%
Cash Flow (DCF)
Fair Value
Market $72.1
-6.55%
Default assumptions
EBITDA Multiple
Fair Value
Market $72.1
-11.26%
Default assumptions
Base valuations use default assumptions. Customize in the Valuator.
Valuation
Financial
Performance
Cash flow to debt coverage
Utah Medical Products, Inc. cash flow to debt ratio of 6.53K% indicates that the company generates enough cash to cover a substantial portion of its debt. This level indicates very strong financial health.
Free cash flow growth
Utah Medical Products, Inc.'s free cash flow has decreased 1.88% from $14.60M last year to $14.32M, signaling decreasing performance
Debt-to-equity ratio
Utah Medical Products, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.
Debt-to-equity trend
Utah Medical Products, Inc.'s debt has decreased relative to shareholder equity from 0.00 last year to 0.00 today, signaling strengthened financials
Net debt to EBITDA
Utah Medical Products, Inc. has a net cash position, so leverage is healthy.
Interest coverage
Interest expense is not separately reported in Utah Medical Products, Inc.'s latest filing, so interest coverage cannot be calculated.
Profit margin growth
Utah Medical Products, Inc.'s profit margin has decreased (14.38%) in the last year from 33.92% to 29.04%, signaling decreasing performance
Current ratio
Utah Medical Products, Inc.'s short-term assets of $97.74M exceed its short-term liabilities of $2.60M
Return on assets
Utah Medical Products, Inc.'s return on assets of 8.42% is higher than the 5.00% threshold, indicating efficient asset utilization
Return on equity
Utah Medical Products, Inc.'s return on equity of 8.74%, is lower than 15.00%, indicating bad performance
Earnings quality
Utah Medical Products, Inc.'s operating cash flow exceeds its net income, indicating high-quality earnings backed by actual cash generation
Earnings stability
Utah Medical Products, Inc. had positive net income in 5 out of 5 years, indicating stable and consistent earnings
Positive free cash flow
Utah Medical Products, Inc. has positive free cash flow, indicating the company generates cash after capital expenditures
Free cash flow yield
Utah Medical Products, Inc. has a free cash flow yield of 6.31%, which is above the 2.00% threshold, indicating strong cash generation relative to market value
Earnings growth
Utah Medical Products, Inc.'s yearly earnings has decreased 18.65% since last year from $13.87M to $11.29M, signaling decreasing performance
Revenue growth
Utah Medical Products, Inc.'s yearly revenue has decreased 5.83% since last year from $40.90M to $38.52M, signaling decreasing performance
Return on invested capital
ROIC 6.83% (Source: FMP key-metrics). In the 5–10% partial-credit band. Score: 1 of 2. This band sits within the typical US weighted-average cost of capital range. Methodology choice can change the conclusion: under FMP's invested-capital definition the company is at or near its cost of capital; under narrower operating-capital definitions the same company may score higher. Invested capital here includes equity, non-current liabilities, and short-term debt. Cash is not subtracted. See methodology.
3-year revenue CAGR
Utah Medical Products, Inc.'s 3-year revenue CAGR of -9.68% is negative, indicating declining revenue over the past 3 years
Revenue consistency
Utah Medical Products, Inc. had revenue growth in only 2 out of 5 years, indicating inconsistent revenue performance
Return on equity consistency
Utah Medical Products, Inc. had positive ROE in 5 out of 5 years, indicating consistent and reliable returns on equity
Cash Flow Valuation (DCF)
Utah Medical Products, Inc. is overvalued relative to its fair value price of 67.38 based on Discounted Cash Flow model
Earnings yield (TTM)
Utah Medical Products, Inc. has an earnings yield of 4.62%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings
EBITDA Valuation
Utah Medical Products, Inc. is overvalued relative to its fair value price of 63.98 based on EBITDA multiple model
EV/EBITDA (FY)
Utah Medical Products, Inc. has an EV/EBITDA ratio of 8.30x, which is below the 20.00x threshold, indicating reasonable valuation relative to its operating earnings
PEG ratio (TTM/FY)
Utah Medical Products, Inc. has a PEG-ratio over 1 which is considered overvalued
Price-to-book ratio (FY)
Utah Medical Products, Inc. has a price-to-book ratio of 1.86x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value
Price-to-sales ratio (TTM)
Utah Medical Products, Inc. has a price-to-sales ratio of 6.29x, which is below the 8.00x threshold, indicating reasonable valuation relative to its revenue